GlassScriptPhysician profile
Natasha Shah
NPI 1699439992
$2,817.49
in general payments reported to CMS, 2019-2025
20 companies · $658 in 2025
The $658 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,014 · 2023: $689 · 2024: $457 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $639.40 | 2022-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.21 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $365.06 | 2022-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $250.00 | 2022-2023 | Wegovy |
| Abbott Laboratories | $170.44 | 2022 | |
| Gilead Sciences, INC. | $149.98 | 2025 | |
| Neurocrine Biosciences, INC. | $139.77 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $77.50 | 2023 | |
| Abbvie INC. | $58.94 | 2025 | |
| Glaxosmithkline, LLC. | $58.08 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $52.69 | 2025 | Breztri, Airsupra |
| Pfizer INC. | $46.83 | 2022-2024 | |
| Dexcom, INC. | $39.67 | 2022-2023 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.03 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $18.98 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $15.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2025 | |
| Mylan Specialty L.P. | $12.83 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.